Virios Therapeutics logged a 75.9% change during today's afternoon session, and is now trading at a price of $1.1 per share.
Virios Therapeutics shares moved -83.6% over the last 52 weeks, with a high of $9.11 and a low of $0.22. During this time, the stock lagged the S&P 500 index by -83.0%. As of January 2022, the company's 50-day average price is $0.4. Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The small-cap Health Care company has 4 full time employees and is based in Alpharetta, GA. Virios Therapeutics has not offered any dividends in the last year.
The Company Has Irregular and Negative Cash Flows:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (k) | $0 | $0 | $0 | $0 |
| Revenue Growth | n/a | n/a | n/a | n/a |
| Operating Margins | n/a | n/a | n/a | n/a |
| Operating Margins Growth | n/a | n/a | n/a | n/a |
| Net Margins | n/a | n/a | n/a | n/a |
| Net Margins Growth | n/a | n/a | n/a | n/a |
| Earnings Per Share | -$0.51 | -$2.1 | -$1.92 | -$1.1 |
| EPS Growth | n/a | -311.76% | 8.57% | 42.71% |
| Diluted Shares (MM) | 5 | 5 | 8 | 18 |
| Free Cash Flow (k) | -$2,092 | -$3,895 | -$15,690 | -$11,468 |
| FCF Growth | n/a | -86.18% | -302.79% | 26.91% |
Virios Therapeutics has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. Its forward P/E isn't meaningful either because its guidance EPS is -0.42.
On the other hand, Virios Therapeutics is possibly undervalued in terms of its net assets because its P/B ratio is 2.8 compared to its sector average of 4.16.
Most of the Market Indicators on Virios Therapeutics Are Negative:
The company has an average amount of shares sold short since 2.2% of the company's shares are tied to short positions. Institutions own 10.7% of Virios Therapeutics's shares, while the insider ownership rate stands at 12.05%. The biggest shareholder is Renaissance Technologies, LLC with a 1% stake in the company worth approximately $258,940.
